Transporter-mediated renal handling of nafamostat mesilate

被引:16
作者
Li, Q
Sai, Y
Kato, Y
Muraoka, H
Tamai, I
Tsuji, A
机构
[1] Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan
[2] Sci Univ Tokyo, Fac Pharmaceut Sci, Noda, Chiba 2788510, Japan
关键词
renal transport; organic cation transporters; nafamostat mesilate;
D O I
10.1002/jps.10534
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nafamostat mesilate (NM) is a serine-protease inhibitor that is rapidly eliminated from the circulation and accumulated in the kidney. This study was conducted to characterize the mechanism of NM transport in the kidney because a serious side effect of NM-induced hyperkalemia may be related to accumulation of NM in the kidney. Measurements of uptake of NM in vivo by the kidney uptake index (KUI) method and of transport in an in vitro-cultured LLC-PK1 cell system suggested the involvement of an organic cation transporter (OCT). To clarify the involvement of OCTs located in the basolateral membrane of proximal tubules, we evaluated NM transport by OCTs expressed in Xenopus laevis oocytes. The IC50 values of NM on [C-14]TEA ([C-14]tetra-ethylammonium) uptake by rOCT1, rOCT2, and hOCT2 were 50, 0.5, and 20 muM, respectively, and NM was concluded to be a substrate of OCTs. To investigate the transport of NM across the brush-border membrane, we examined the uptake of NM into brush-border membrane vesicles (BBMVs) isolated from rat renal cortex. NM was taken up into the BBMVs, and the uptake was decreased by unlabeled NM and temperature, implying that a transporter(s) is also involved in NM transport across the apical membrane. NM was not a substrate of hOCTN1, hOCTN2, or P-gp, implying the involvement of some unknown transporter(s). Thus, renal accumulation of NM can be explained by the involvement of the basolateral OCTs, though the influence of the apical membrane transporter remains to be clarified. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:262 / 272
页数:11
相关论文
共 39 条
[1]   PHARMACOLOGICAL STUDIES OF FUT-175, NAFAMSTAT MESILATE .1. INHIBITION OF PROTEASE ACTIVITY IN INVITRO AND INVIVO EXPERIMENTS [J].
AOYAMA, T ;
INO, Y ;
OZEKI, M ;
ODA, M ;
SATO, T ;
KOSHIYAMA, Y ;
SUZUKI, S ;
FUJITA, M .
JAPANESE JOURNAL OF PHARMACOLOGY, 1984, 35 (03) :203-227
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   SELECTIVE AVAILABILITY OF PROTEIN-BOUND ESTROGEN AND ESTROGEN CONJUGATES TO THE RAT-KIDNEY [J].
CHAUDHURI, G ;
VERHEUGEN, C ;
PARDRIDGE, WM ;
JUDD, HL .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1987, 10 (03) :283-290
[4]   Prostasin is a glycosylphosphatidylinositol-anchored active serine protease [J].
Chen, LM ;
Skinner, ML ;
Kauffman, SW ;
Chao, J ;
Chao, L ;
Thaler, CD ;
Chai, KX .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (24) :21434-21442
[5]  
GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266
[6]   Cloning and characterization of two human polyspecific organic cation transporters [J].
Gorboulev, V ;
Ulzheimer, JC ;
Akhoundova, A ;
UlzheimerTeuber, I ;
Karbach, U ;
Quester, S ;
Baumann, C ;
Lang, F ;
Busch, AE ;
Koepsell, H .
DNA AND CELL BIOLOGY, 1997, 16 (07) :871-881
[7]  
HITOMI Y, 1985, HAEMOSTASIS, V15, P164
[8]   Cellular and molecular aspects of drug transport in the kidney [J].
Inui, K ;
Masuda, S ;
Saito, H .
KIDNEY INTERNATIONAL, 2000, 58 (03) :944-958
[9]   PHARMACOLOGICAL STUDIES OF FUT-175, NAFAMOSTAT MESILATE .5. EFFECTS ON THE PANCREATIC-ENZYMES AND EXPERIMENTAL ACUTE-PANCREATITIS IN RATS [J].
IWAKI, M ;
INO, Y ;
MOTOYOSHI, A ;
OZEKI, M ;
SATO, T ;
KURUMI, M ;
AOYAMA, T .
JAPANESE JOURNAL OF PHARMACOLOGY, 1986, 41 (02) :155-162
[10]   Inhibition of prostasin secretion by serine protease inhibitors in the kidney [J].
Iwashita, K ;
Kitamura, K ;
Narikiyo, T ;
Adachi, M ;
Shiraishi, N ;
Miyoshi, T ;
Nagano, J ;
Tuyen, DG ;
Nonoguchi, H ;
Tomita, K .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (01) :11-16